SEARCH

SEARCH BY CITATION

References

  • 1
    Future II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007; 356: 191527.
  • 2
    Ault KA. Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. Lancet 2007; 369: 18618.
  • 3
    Garland SM, Hernandez-Avila M, Wheeler CM et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007; 356: 192843.
  • 4
    Villa LL, Costa RL, Petta CA et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 2005; 6: 2718.
  • 5
    Villa LL, Costa RL, Petta CA et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer 2006; 95: 145966.
  • 6
    Stanley M, Lowy DR, Frazer I. Prophylactic vaccines: underlying mechanisms. Vaccine 2006; 24: S10613.
  • 7
    Markowitz LE, Dunne EF, Saraiya M, Lawson HW, Chesson H, Unger ER. Quadrivalent human papillomavirus vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2007; 56: 124.
  • 8
    Randall DP. Guillain-Barre syndrome and immunizations. Dis Mon 2010; 56: 2938.
  • 9
    Salemi S, D’Amelio R. Could autoimmunity be induced by vaccination? Int Rev Immunol 2010; 29: 24769.
  • 10
    Chen RT, Pless R, Destefano F. Epidemiology of autoimmune reactions induced by vaccination. J Autoimmunol 2001; 16: 30918.
  • 11
    Rubin DB. Multiple Imputation for Nonresponse in Surveys. New York: John Wiley & Sons, Inc., 1987.
  • 12
    Block SL, Brown DR, Chatterjee A et al. Clinical trial and post-licensure safety profile of a prophylactic human papillomavirus (types 6, 11, 16, and 18) l1 virus-like particle vaccine. Pediatr Infect Dis J 2010; 29: 95101.
  • 13
    Chen RT, Rastogi SC, Mullen JR et al. The Vaccine Adverse Event Reporting System (VAERS). Vaccine 1994; 12: 54250.
  • 14
    Slade BA, Leidel L, Vellozzi C et al. Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine. JAMA 2009; 302: 7507.